Clinical Trial

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
Protocol Amendment History 4 changes
notable Trial sites expanded: 22 -> 35 locations 2026-06-16
notable Trial sites expanded: 13 -> 22 locations 2026-05-02
notable Trial sites expanded: 10 -> 13 locations 2026-04-18
notable Trial sites expanded: 7 -> 10 locations 2026-04-03
Trial Details
NCT Number NCT07454837
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Chronic Hepatitis D
Enrollment 120 participants
Start Date 2026-02-26
Primary Completion 2027-08-31 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-29